

Remarks

Currently Claims 1-12, 16 and 19-26 are pending.

Claims 13-15 are canceled. Claims 17-18 are canceled and re-written as new claims 19-21 and 25-26, respectively.

Claims 1-12 and 16 are amended herein. Claim 1 is amended to correct the subscripts in the various chemical formulas, to change "represents" to "is" or "are" as appropriate, and to change plural to singular. Claims 2, 11 and 12 are amended to remove the parenthetical subspecies embodiment. Claims 3-11 and 16 are amended to remove multiple dependencies to reduce claim fees. The foregoing amendments do not narrow the scope of the claims and are not made for reasons of patentability. No new matter is added.

New claims 19-26 are added. Support for new claims 19-21 can be found in Applicants' specification, including at original claim 17. Support for new claims 22-23 can be found in Applicants' specification, including at page 7, lines 34-38. Support for new claim 24 can be found in Applicants' specification, including at page 9, line 20. Support for new claims 25-26 can be found in Applicants specification, including at original claim 18. No new matter is added.

Applicants have also amended the specification to recite priority application information and to provide an abstract on a separate page.

Entry of the foregoing amendments is respectfully requested.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

²²
Date: 20 July, 2004
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
email: Lorie.A.Morgan@gsk.com